welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
-
BIOPHYTIS receives orphan drug designation in the United States for Sarconeos in Duchenne muscular dystrophy (DMD)BIOPHYTIS, a biotechnology company speci...
-
Nearly Half of Duchenne Muscular Dystrophy Patients Are Candidates for Gene TherapiesMore than 40 percent of boys with Duchen...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
-
Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociati...Santhera Pharmaceuticals and Idorsia Ltd...